Allogene Therapeutics Inc (NASDAQ:ALLO) Given Average Rating of “Buy” by Brokerages
Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) have received an average recommendation of “Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $36.13.
A number of brokerages have commented on ALLO. Zacks Investment Research upgraded Gerdau from a “sell” rating to a “hold” rating in a research report on Monday, May 13th. William Blair restated a “buy” rating on shares of Allogene Therapeutics in a research report on Monday, April 15th. Oppenheimer began coverage on Allogene Therapeutics in a research report on Friday, May 3rd. They issued an “outperform” rating and a $45.00 price target for the company. Piper Jaffray Companies upgraded F5 Networks from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $157.00 to $163.00 in a research report on Friday, March 29th. Finally, Stifel Nicolaus set a $154.00 price target on argenx and gave the stock a “buy” rating in a research report on Wednesday, May 22nd.
In related news, insider Alison Moore sold 48,828 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $26.76, for a total transaction of $1,306,637.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $29.38, for a total value of $56,373,021.90. The disclosure for this sale can be found here. Company insiders own 36.50% of the company’s stock.
ALLO traded down $0.23 during midday trading on Tuesday, reaching $28.01. The company had a trading volume of 247,463 shares, compared to its average volume of 474,484. The company has a current ratio of 17.48, a quick ratio of 17.48 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average price is $26.87. The firm has a market capitalization of $3.40 billion and a P/E ratio of -4.26. Allogene Therapeutics has a 1 year low of $21.67 and a 1 year high of $35.55.
Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. Research analysts forecast that Allogene Therapeutics will post -1.94 EPS for the current fiscal year.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.